BioChem, Unimed deal

BCHXF's BioChem Therapeutic Inc. subsidiary licensed the Canadian rights to UMED's testosterone products, Androgel-DHT and Androgel, and the anti-parasitic drug NTZ. BCHXF invested $488,923 in UMED through the purchase of 50,771 common shares at $9.63. UMED has 8.6 million shares outstanding prior to the sale. ...